All In Biotech

Drug Trial Radar · NCT06861101

Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults

A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JT002 in Adult Patients With Seasonal Allergic Rhinitis

Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 370 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

370

Actual

Start

Feb 24, 2025

Primary completion

May 6, 2025

Study completion May 14, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study included three phases: the treatment introduction period (4-7 days before randomization), the treatment period (14 days after randomization) and the follow-up period (7 days after the last dose). Eligible participants in this study entered the 4-7 day treatment introduction period. After completing the treatment introduction period, patients who did not meet the random exclusion criteria of this study were randomly assigned to one of the 4 dose cohorts in a 1:1:1:1 ratio, with 80 patients planned to be enrolled in each cohort, and then randomly assigned to receive the investigational product or placebo in the cohort at a 4:1 ratio, for a total of 320 patients. Participants were stratified by prior Drug therapy for Rhinitis allergic. Ultimately, the proportion of patients receiving 200 μg BID, 400 μg BID, 400 μg QD, 800 μg QD and placebo was 1:1:1:1:1 (64 patients in each group).

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • JT002 Nasal sprayDrug

    200 μg BID, 400 μg BID, 400 μg QD, 800 μg QD, 64 patients per cohort, total 256 patients for treatment 14 days

  • PlaceboDrug

    Total 64 patients for treatment 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. rTNSSTime frame: During the 14-day treatment period

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Youan Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Wuwei People's Hospital

    Wuwei, Gansu, China

  • Shenzhen Nanshan District People's Hospital

    Shenzhen, Guangdong, China

  • Shenzhen University General Hospital

    Shenzhen, Guangdong, China

  • Zhengzhou Central Hospital

    Zhengzhou, Hanan, China

  • The Second Hospital of Baoding City

    Baoding, Hebei, China

  • Cangzhou Central Hosptial

    Cangzhou, Hebei, China

  • Hebei Retro China Central Hosptial

    Hebei, Hebei, China

  • Hebei Provincial Hospital of Traditional Chinese Medicine

    Shijiazhuang, Hebei, China

  • The Third Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The First Affiliated Hospital of Hebei North University

    Zhangjiakou, Hebei, China

  • The People's Hospital of daqing

    Daqing, Heilongjiang, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Jingzhou Central Hospital (Jingzhou Hospital affiliated to Yangtze University)

    Jingzhou, Hubei, China

  • Wuhan Central Hospital

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • BaogangHospital of InnerMongolia

    Baotou, InnerMongolia, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Shengjing Hospital Affiliated to China Medical University

    Shenyang, Liaoning, China

  • Liaoning Provincial Health Industry Group Iron Coal General Hospital

    Tieling, Liaoning, China

  • Chifeng municipal hospital

    Chifeng, Mongolia, China

  • People's Hospital of Ningxia Hui Autonomous Region

    Yinchuan, Ningxia, China

  • The First People's Hospital of Yinchuan

    Yinchuan, Ningxia, China

  • Zibo central hospital

    Zibo, Shandong, China

  • Eye&Ent Hospital of fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center

    Shanghai, Shanghai Municipality, China

  • Heping hospital affiliated to Changzhi medical college

    Changzhi, Shanxi, China

  • Second hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • First Hospital Of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Shanxi Bethune hospital

    Taiyuan, Shanxi, China

  • The First Affiliated Hospital of Xi 'an Jiaotong University

    Xi’an, Shanxi, China

  • The Second Affiliated Hospital of Xi 'an Jiaotong University

    Xi’an, Shanxi, China

  • Xi'an DaXing Hospital

    Xi’an, Shanxi, China

  • Xi'an High tech Hospital

    Xi’an, Shanxi, China

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.